Production of horse foals via direct injection of roscovitine-treated donor cells and activation by injection of sperm extract.

The study investigates different methods of nuclear transfer involving donor cells and activation techniques for producing horse embryos. The results demonstrated that using roscovitine-treated donor cells and standard activation protocols can produce viable cloned foals.

Understanding the Methodology Used

• The process of nuclear transfer was implemented by directly injecting donor cells through a piezo drill— a precise tool used in micromanipulation, and standard activation was done by injecting sperm factor before culturing with 6-dimethylaminopurine.
• Two types of donor cells were used – roscovitine-treated cells and confluent cells. Roscovitine is a cyclin-dependent kinase inhibitor that can induce cell cycle arrest, thereby halting cell growth, while confluent cells are cells grown to occupy the entire surface of the growth medium.
• The process of activation also involved the additional injection of roscovitine or a period of culture with cycloheximide, a substance that inhibits protein synthesis.

Results and Conclusions of the Study

• Blastocyst (early embryo) development showed no significant difference between the embryos produced from roscovitine-treated cells and the ones from confluent donor cells. This suggests that roscovitine treatment neither positively nor negatively impacts the development of horse embryos into blastocysts.
• The addition of roscovitine or the culture phase with cycloheximide at the time of activation did not affect the development into blastocysts. This is an important finding as it suggests that different activation procedures can be used without compromising embryo development.
• Eight blastocysts which were generated using the roscovitine-treated cells and standard activation protocol resulted in three pregnancies. Out of these, two led to the successful delivery of viable foals. However, when a roscovitine injection was used in the activation of roscovitine-treated cells, the subsequent pregnancy was lost before 114 days’ gestation. This indicates that while roscovitine may not impact the initial embryo development, it might have unforeseen effects in maintaining a pregnancy.
• When the activation process involved cycloheximide in conjunction with confluent donor cells, no successful pregnancies occurred, suggesting a possible adverse effect of this combination on horse embryonic development.
• The research concluded that using roscovitine-treated donor cells results in equivalent blastocyst production to that of confluent donor cells, thus providing an alternative approach for horse cloning.